Palliative Care: Physician Communication and Patient Comprehension
The consensus from our audience was almost exactly evenly split between discussing palliative care with patients at the beginning of treatment and after all treatment options have failed.<br><br>Recent research, however, suggests that palliative care as a method to ease the symptoms of cancer treatment is most effective at the onset of treatment.
Very few, only 12%, of respondents indicated that patients understand palliative care before it is explained.<br><br>While this is very much in line with the research, experts have indicated the need for increased broad awareness of palliative care in order to increase the effectiveness and decrease misconceptions and fear surrounding this topic.
Almost all respondents, 98.85% see a need for better training for physicians who are discussing palliative care with their patients.<br><br>To read more about palliative care, visit <a href="http://www.cancertherapyadvisor.com/palliative-care/section/2450/">http://www.cancertherapyadvisor.com/palliative-care/section/2450/</a>.
The Palliative Care in Oncology Symposium recently took place in Boston, Massachusetts, and focused on patient-centered care across the cancer continuum.
With this in mind, Cancer Therapy Advisor conducted a community poll that asked our readers about their experience in dealing with issues surrounding the discussion of palliative care with their patients.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy